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Although the growth-promoting effects of insulin-like growth
factor II (IGF-II) have been intensively studied, the acute actions
of this hormone on glucose metabolism have been less well
evaluated, especially in skeletal muscle of humans. We and other
groups have shown that IGFs reduce glycaemic levels in humans
and stimulate glucose uptake in rat muscle. The purpose of the
present study was to evaluate the effect of IGF-II on glucose
transport in muscle of normal and obese patients with and
without non-insulin-dependent diabetes mellitus (NIDDM), as
well as to identify the receptor responsible for this action. 2-
Deoxyglucose transport was determined in vitro using a muscle-
fibre strip preparation. IGF-II binding and stimulation ofglucose
transport by IGF-II were investigated in biopsy material of
rectus abdominus muscle taken from lean and obese patients and
obese patients with NIDDM at the time of surgery. In the lean
group, IGF-II (100 nM) stimulated glucose transport 2.1-fold,
INTRODUCTION
Insulin-like growth factor II (IGF-II) is a single-chain poly-
peptide, which shows high sequence homology and similarities in
tertiary structure to IGF-I and proinsulin [1]. In addition to
growth promotion, IGFs also exert acute metabolic effects that
are very similar to those produced by insulin. IGFs circulate in
the blood bound to specific IGF-binding proteins which probbly
protect them from degradation and regulate the availability of
both growth factors to the tissues [2-4]. IGFs are mainly
produced in the liver, but they are also synthesized locally in
several tissues, including skeletal muscle [5]. IGF-I, a mediator
of the growth-promoting effect of growth hormone, also mimics
many effects of insulin [6,7]. It has been shown to reduce
glycaemic levels in normal [8-10] and diabetic humans [11,12].
Incubation of human or rat skeletal muscle with IGF-I increases
the rates of glucose phosphorylation [6,13,14], glycolysis and
glycogen synthesis [6,15,16].
IGF-II is present in plasma at three to four times the con-
centration of IGF-I and seems not to be regulated by growth
hormone [17]. Several studies have shown that high levels of
IGF-II in human patients with extrapancreatic tumours [17-21]
appear to be responsible for the development of hypoglycaemia,
as well as stimulation of synthesis of tissue glycogen and lipid in
rats [16]. Furthermore, IGF-II increases glucose uptake in rat and
human adipocytes [22-24], actions considered to be mediated via
which was slightly less than stimulation by insulin (2.8-fold) at
the same concentration. Binding of IGF-II was approx. 25 % of
that of insulin at 1 nM concentrations of both hormones. Obesity
with or without NIDDM significantly reduced IGF-II-stimulated
glucose uptake compared with the lean group. In order to
explore which receptor mediated the IGF-II effect, we compared
glucose uptake induced by IGF-II and two IGF-II analogues:
[Leu27]IGF-II, with high affinity for the IGF-II/Man 6-P receptor
but markedly reduced affinity for the IGF-I and insulin receptors,
and [Arg54,Arg55]IGF-II, with high affinity for the IGF-I and
insulin receptors but no affinity for the IGF-II/Man 6-P receptor.
The potency of [Arg54,Arg55]IGF-II was similar to that of IGF-
II, whereas [Leu27]IGF-II had a very diminished effect. Results
show that IGF-II is capable of stimulating muscle glucose uptake
in lean but not in obese subjects and this effect seems not to be
mediated via an IGF-II/Man 6-P receptor.
the insulin receptor. However, other authors have suggested that
some biological effects of IGF-II are mediated by the IGF-
II/Man 6-P receptor [25-28]. Several in vitro studies [27] have
demonstrated the ability of IGF-II to stimulate glucose transport
in rat, as well as in human, skeletal muscle [29]. Shimizu et al. [30]
showed that, in myotubes, the effect of IGF-I and IGF-II
appeared to be mediated via the IGF-I receptor. It seems likely
that, in skeletal muscle, the metabolic effects of IGFs are mainly
exerted via an IGF-I receptor [6,31,32]. The IGF-I receptor has
an a-subunit with binding capacity and a f-subunit with tyrosine
kinase activity [33,34]. The IGF-I receptor binds both IGF-I and
IGF-II, although the affinity for IGF-I is somewhat higher. In
contrast with the IGF-I and insulin receptors, the IGF-II/Man
6-P receptor is a single transmembrane protein which does not
have tyrosine kinase activity [35-38]. IGF-II is capable ofreacting
with three different receptors: those for IGF-II/Man 6-P and
IGF-I as well as the insulin receptor, although with a lower
affinity. The existence of at least three different receptors with
overlapping specific binding complicates the assignment of a
particular response to a particular receptor and obscures the
identity of the receptor via which the biological actions of IGF-
II are mediated.
In the present study, we have investigated the IGF-II stimu-
lation of glucose transport into human muscle from lean and
obese subjects and obese patients suffering from non-insulin-
dependent diabetes mellitus (NIDDM). Furthermore, we have
Abbreviations used: IGF-I, IGF-Il, insulin-like growth factor I, ll; NIDDM,
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looked at which receptor mediates the IGF-II effect, by com-
paring glucose uptake induced by IGF-II with that induced by
two IGF-II analogues [39,40], [Leu27]IGF-II and [Arg54,Arg55]
IGF-II.
MATERIALS AND METHODS
Materials
1251-insulin, 1251-IGF-I, 1251-IGF-II, IGF-I and IGF-II were gifts
from Eli Lilly, Indianapolis, IN, U.S.A. IGF-II was also pur-
chased from Gro-pep. [U-_4C]Sorbitol (150-250 mCi/mmol) and
2-[1,2-3H(n)]-deoxy-D-glucose (30.3 Ci/mmol) were obtained
from Du Pont-NEN (Boston, MA, U.S.A.). [Arg54,Arg55]IGF-
II and [Leu27]IGF-II (mutant recombinant human IGF-II
analogues) were obtained from Daiichi Pharmaceutical Co.
(Tokyo, Japan). Unless otherwise stated, all other chemicals
were obtained from Sigma (St. Louis, MO, U.S.A.).
Human subjects
Abdominal-muscle samples were obtained from five morbidly
obese patients with NIDDM and five morbidly obese and ten
lean patients with normal glucose-tolerance tests. All the patients
not known to have NIDDM underwent an oral glucose-tolerance
test, as recommended by the National Diabetes Data Group [41],
to establish the diagnosis of normal or NIDDM. The morbidly
obese patients had been admitted to the hospital to undergo
gastric bypass for the treatment of morbid obesity and the lean
patients had been admitted for elective hysterectomy. Other than
obesity and NIDDM, none of the subjects had any diseases or
had taken any medications known to alter carbohydrate or lipid
metabolism. NIDDM patients who were taking sulphonylureas
and/or insulin discontinued the medication 3 weeks and 1 week
respectively before surgery. Detailed clinical information on this
patient population is presented in Table 1. Written consent was
obtained from all patients after they had been informed about
the nature and potential risks of the study. The patients under-
went surgery after an overnight fast. General anaesthesia was
induced with a short-acting barbiturate and maintained by fen-
tanyl and a nitrous oxide/oxygen mixture. Only saline was given
intravenously before the biopsy. After exposure of the rectus
abdominus muscle, a piece 3 cm x 2 cm x 2 cm was removed.
The project was approved by the East Carolina University
Policy and Review Committee on Human Research.
Table 1 Clinical and biochemical characteristics of the
patients
three groups of
Values are means or means + S.E.M.
Lean Obese Obese
control control NIDDM
(n = 10) (n = 5) (n = 5)
Age (years)
Weight (kg)
Height (cm)
Body mass
index (kg/M2)
Fasting glucose
concentration (mM)
41.4+3
63
160
24.6 + 2
35.8 +3
164
164
46.1 + 6
38.8 +4
120
159
48+4
4.5+0.2 5.7+1 10+2.5
Binding assays for Insulin, IGF-I and IGF-II
Muscle samples for receptor-binding studies were frozen between
aluminium tongs, cooled in solid CO2 as quickly as possible
after excision and stored at -70° C until analysed. Partial
purification of the insulin and IGF receptors were accomplished
by wheat-germ-agglutinin chromatography. Binding of 1251_
insulin, 125I-IGF-I and 125I-IGF-II to the partially purified
receptors was measured at 4 ° C for 16 h as previously described
[42]. The data were expressed as specific hormone binding after
subtraction of non-specific binding from total binding. Non-
specific hormone binding is the radioactivity associated with the
receptor in the presence of 1 ,uM labelled hormone, and in this
study was less than 20 % of the total binding. Cross-linking of
solubilized receptors with 125I-IGF-II was accomplished with
disuccinimidyl suberate [43,44], and PAGE was performed in
7.5 % gel under reduced conditions.
Transport of 2-deoxyglucose by muscle-fibre strips
A specially constructed clamp (3 cm wide) was placed on muscle
tissue before excision, and then the clamp and muscle biopsy
material were quickly transported to the laboratory in oxygenated
Krebs-Henseleit buffer. Muscle-fibre strips weighing 50-80 mg
were teased from the mounted muscle, and a smaller clamp was
placed on each muscle strip before it was cut free [45]. The
muscle-fibre strip in the clamp was then incubated in vitro in
Krebs-Henseleit buffer with BSA and pyruvate as previously
described [45] or by a modification (muscle in 1 cm small clamps
incubated at 29 ° C with 0.5 mM Ca2+). 2-[3H]Deoxyglucose
transport was assayed as previously described [45]. These changes
in the incubation conditions reduced basal glucose uptake. The
maximum hormone-stimulated glucose uptake was similar under
both conditions.
Statistical analysis
Stimulation of glucose transport induced by the different hor-
mones were analysed using one-way analysis of variance and
expressed as a mean+ S.E.M. Differences between groups were
detected using the Student-Newman-Keuls test with significance
set at the P < 0.05 level.
RESULTS
IGF-II binding
To demonstrate the specific binding ofIGF-II to its own receptor,
displacement of 1251-insulin, 125I-IGF-I and 1251-IGF-II was
investigated (Figure 1). Approx. 100 times more IGF-II than
insulin was required to displace half of the bound insulin (Figure
la), showing that IGF-II has a relatively low affinity for the
insulin receptor. IGF-II, however, did have a reasonably high
affinity for the IGF-I receptor as shown by the fact that only
about 10 times more IGF-II was required to displace half of the
125I-IGF-I than unlabelled IGF-I (Figure Ib). On the other hand,
IGF-I has a very low affinity for the IGF-II/Man 6-P receptor
(Figure Ic).
To demonstrate further the presence of IGF-II/Man 6-P
receptor, 125I-IGF-II was cross-linked to wheat-germ-agglutinin-
purified receptors and then separated by electrophoresis. Figure
2 shows a 230 kDa band which is displaced by unlabelled IGF-
II. Specific binding of IGF-II to the ac-subunit (130 kDa) of the
IGF-I receptor can be seen. A 70 kDa band was displaced by
both IGF-I and IGF-II, at a I ,uM concentration of each of the
growth factors. It is our belief that this protein could be a
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Figure 1 Displacement of 121-insulin (a), 126-IGF-I (b), 151-IGF-ll (c) byunlabelled Insulin, IGF-I and IGF-11 from wheat-germ-agglutinin-purifled
receptors
Each data point is the mean + S.E.M. for four observations. 0, Displacement by insulin; A,
displacement by IGF-I; *, displacement by IGF-II.
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Figure 2 Electrophoretic separation of wheat-germ-agglutinin-purified
receptors affinity-cross-linked to 151-IGF-ll
Displacement of 1251-IGF-ll from the IGF-II/Man 6-P receptor (230 kDa) and the a-subunit of
the IGF-I receptor (130 kDa) is demonstrated in lane 2. Insulin and IGF-I displace 1251-IGF-ll
from the a-subunit of the IGF-I receptor but not the IGF-II/Man 6-P receptor (lanes 3 and 4).
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soluble fraction of the IGF-II/Man 6-P receptor or an as yet
undescribed IGF-binding protein.
Binding of 1251-insulin, 1251-IGF-I and 1251-IGF-II was mea-
sured at 0.1 nM hormone to determine the relative binding
capacities of these hormones to a wheat-germ-agglutinin-purified
preparation of receptors from human skeletal muscle in the
presence and absence of a large excess of unlabelled hormone
(1 ,uM). As we have shown elsewhere [42], there was approx.
equal binding for IGF-I and IGF-II, and IGF-II binding was
approx. 25 % of that for insulin.
Stimulation of glucose transport
To determine whether IGF-II can increase glucose transport in
human muscle, 2-deoxyglucose transport was measured in
Figure 3 Stimulation of 2-deoxyglucose transport Into muscle-fibre strips
by IGF-11, insulin and IGF-I
Values are means+S.E.M. for the number of observations (n) indicated.
muscle-fibre strips from lean patients at several hormone concen-
trations. The data in Figure 3 demonstrate that IGF-II at a
concentration of 100 nM maximally stimulates glucose transport
approx. 2.1-fold. Increasing the concentration of IGF-Il from
1 nM to gM induced a dose-response increase in the 2-
deoxyglucose transport. At concentrations as low as 1 nM, IGF-
II stimulated 2-deoxyglucose transport to 36% above basal.
For comparison, stimulation of 2-deoxyglucose transport by
insulin and IGF-I is also shown in Figure 3. At 100 nM
concentration, insulin stimulated 2-deoxyglucose transport
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Table 2 Stimulation of 2-deoxyglucose transport (nmol/min per g of wet
issue) Into muscle-fibre strips fmm lean, obes and obese-NIDDM patients
by IGF-11 (100 nM), [Arg",Arg"]IGF-I1 (100 nM) and [Leu"JIGF-11 (100 nM)
Values (means ± S.E.M.) are expressed as increase above basal. Basal glucose-transport rates
for lean, obese and obese-NIDDM patients were 2.6+ 0.15, 2.3+1 and 2.4+ 0.4 nmol/min
per g of wet tissue respectively. *P < 0.05 compared with lean patients.
Lean Obese Obese-NIDDM
(n = 4) (n = 5) (n = 5)
IGF-11
[Leu27]IGF-11
[Arg54,ArgS5]IGF-11
2.58 + 0.15
1.05+ 0.4
2.67 + 0.55
0.42+1*
0.32 + 0.2
0.5+0.2*
1.26+ 0.4*
0.75+ 0.41
1.56+0.6*
slightly more than IGF-II or IGF-I, but the differences were
not statistically significant. Insulin (100 nM) stimulated glucose
transport 2.5-fold or 2.8-fold depending on the conditions (see
the Materials and methods section).
In order to evaluate further which receptor was responsible
for this increase in 2-deoxyglucose transport induced by the
administration of IGF-II, we used two IGF-II analogues with
different affinities for the IGF-II/Man 6-P receptor: [Leu27]IGF-
II, with high affinity for the IGF-II/Man 6-P receptor but
markedly reduced affinity for the IGF-I and insulin receptors,
and [Arg54,Arg55]IGF-II, with high affinity for the IGF-I and
insulin receptors but no affinity for the IGF-II/Man 6-P receptor
[39]. Uptake of 2-deoxyglucose increased 2.1-fold when stimu-
lated with [Arg54,Arg55]IGF-II at a concentration of 100 nM.
This effect was very similar to that induced by IGF-II at the same
concentration. In contrast, [Leu27]IGF-II caused a very much
reduced stimulation of glucose uptake (1.4-fold) (Table 2, lean
patients). To determine whether IGF-II (or any of its analogues)
can increase glucose utilization in obesity or NIDDM, 2-
deoxyglucose transport was measured in muscle-fibre strips from
obese and obese-NIDDM patients at a concentration of
100 nM. In contrast with the lean group, IGF-II did not
significantly stimulate the uptake of 2-deoxyglucose transport in
either of the obese groups (Table 2). [Arg54,Arg55]IGF-II at a
concentration of 100 nM induced a larger stimulation of glucose
uptake than [Leu27]IGF-II in all groups. Stimulation of glucose
transport by [Arg54,Arg55]IGF-II or [Leu27]IGF-II was not
statistically significant compared with the basal 2-deoxyglucose
transport in the obese or obese-NIDDM groups. In Table 2,
values are expressed as increase above basal.
DISCUSSION
In a previous study [12] we demonstrated the effectiveness of
IGF-I as an alternative treatment to insulin in circumstances of
severe insulin-resistance. Furthermore we postulated that IGF-I
administered in very high doses could, in part, mediate its effects
through the IGF-II/Man 6-P receptor. It is apparent that there
is an overlapping of the physiological functions of these two
ligands [46].
To our knowledge, there are no data in the literature evaluating
the effect in vivo of IGF-II on glucose metabolism in humans.
However, an indirect evaluation of the effect that high levels of
IGF-II can produce in humans comes from studies performed in
patients with an extrapancreatic tumour that produces IGF-II
or larger forms of IGF-II (big IGF-II) [17-21]. Even though
several investigators have shown that high levels of IGF-II may
lead to sustained hypoglycaemia, there is uncertainty about
which receptor mediates this effect.
Yu and Czech [7] using multiplication stimulating activity
(IGF-II) showed stimulation of glucose transport in rat soleus
muscle apparently via an IGF-I receptor. Likewise, it has been
shown that IGF-II stimulates glucose transport in L6 myoblasts
probably mediated by an IGF-I receptor [47,48]. The insulin
receptor has also been suggested to be responsible for the acute
metabolic actions of IGF-II on carbohydrate metabolism ob-
served in vivo. Compared with insulin, about 50 times more IGF-
II is required to produce similar responses [49]. In contrast with
these studies, the recent data of Bevan et al. [27] suggest that
IGF-II acts through its own receptor to increase insulin activity
in rat soleus muscle.
Another approach to the determination of which receptor
mediates IGF-II action is the use of specific antibodies to block
the IGF-I receptor or affinity IGF-II cross-linking, thereafter
correlating binding to the IGF-II/Man 6-P receptor with actions
exerted via this receptor [27,50,51]. However, receptor antibodies
may only partially block the binding of ligands and some may
not be fully specific. Therefore IGF-II analogues would appear
to be more useful than receptor antibodies in detecting which
receptor mediates the IGF-II effects [40,52]. We used two IGF-II
analogues with different affinities for the IGF-II/Man 6-P
receptor in order to evaluate which receptor is responsible for the
IGF-II stimulation of glucose transport in human muscle [40,52].
IGF-II at a concentration of 1 nM stimulated basal transport
by 36 %, whereas insulin at the same concentration stimulated
glucose transport by 59%. The observation that submaximal
stimulation of glucose transport occurred at approximately the
same concentration for insulin and IGF-II was an unexpected
finding. As there are fewer IGF-I and IGF-II receptors than
insulin receptors in muscle, we had expected that a higher
concentration of IGF-II would be required to produce stimu-
lation of glucose transport. This result may suggest that a
stronger signal is generated by IGF receptors and that a smaller
percentage occupancy is required to produce a maximal response.
However, IGF-II maximally stimulated the uptake of 2-
deoxyglucose transport at a concentration of 1 ,uM, making it
10-fold less potent than insulin. However, in a previous report
[29], a maximal glucose-transport effect was found in human
quadriceps femoris muscle at an IGF-II concentration of 13 nM
(20 times less potent than insulin). The discrepancy in con-
centration between these studies could in part be explained by
methodological differences, especially the type of muscle and
glucose tracer used. Furthermore the dose-response curve of
Zierath et al. [29] does not show saturation with higher con-
centrations of IGF-II.
Our data show that the stimulation of glucose uptake induced
by [Leu27]IGF-II in the human muscle strips was significantly
lower than that exerted by IGF-II. However, [Arg54,Arg55]IGF-
II stimulated 2-deoxyglucose transport in a similar fashion to
insulin and IGF-I. These two facts indicate that IGF-II mainly
stimulates glucose transport in human muscle via the IGF-I
receptor, and the IGF-II/Man 6-P receptor seems to play a
smaller role in this effect. Stimulation via the insulin receptor is
unlikely because of the low affinity of IGF-II for it.
Our previous data [13] showed a decrease in stimulation by
insulin and IGF-I of glucose transport in muscle of morbidly
obese patients with or without NIDDM. One of the objectives of
the present study was to investigate further the mechanism of
insulin resistance by evaluating whether the muscle of morbidly
obese patients is also resistant to IGF-II. The present report
clearly demonstrates that IGF-II does not stimulate glucose
transport in muscle-fibre strips from obese patients. It seems
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unlikely that the beneficial effect of IGF-I administration in
severe cases of insulin resistance would be mediated via an IGF-
II/Man 6-P receptor, at least in human muscle. However it is
our belief that, in circumstances of severe insulin resistance,
IGF-I (and probably IGF-II) seems to increase insulin sensitivity.
Usala et al. [12] showed that lower concentrations of insulin were
required to maintain euglycaemia for several days after IGF-I
administration in a severe insulin-resistant diabetic patient.
The present report provides a unique evaluation of the role of
the IGF-II/Man 6-P and IGF-I receptors in the mediation of
IGF-II effects on glucose uptake in muscle. The question of
whether IGF-II stimulation of glucose transport in skeletal
muscle has physiological significance remains unanswered.
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